FindMyKOL
Clinical trialNCT07914309Not, yet, recruitingPhase 2Interventional

Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer

NCT07914309 is a phase 2 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is not yet recruiting. It studies Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine and 5 more drugs in Breast Cancer, Triple Negative Breast Cancer and 1 more condition. The registry lists an enrollment of 17 participants at 2 sites in 1 country. The registry lists a start date of 30 Nov 2026 and a primary completion date of 8 Feb 2028. One of its registered investigators has a FindMyKOL profile.

SponsorWashington University School of Medicine →Enrollment17Breast CancerTriple Negative Breast CancerTriple Negative Breast Cancer (TNBC)
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07914309
FieldValue
Registry IDNCT07914309
StatusNot yet recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorWashington University School of Medicine
Enrollment17
Registered sites2
Countries1
ConditionsBreast Cancer, Triple Negative Breast Cancer and Triple Negative Breast Cancer (TNBC)
DrugsCarboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine, Doxorubicin, Famotidine, Olanzapine, Paclitaxel and Pembrolizumab
Start30 Nov 2026
Primary completion8 Feb 2028
Study completion31 May 2033
Last update posted3 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-arm, open-label, phase II trial designed to prospectively evaluate the safety and feasibility of dexamethasone de-escalation in patients undergoing standard neoadjuvant chemotherapy and immunotherapy for triple negative breast cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States2 sites
  • St. Luke's Hospital

    Kansas City

    Timothy Pluard, MDWhitney Hensing, MD
  • Washington University School of Medicine

    St Louis

    Alaina Kessler, MD, MPHAndrew Davis, MDAshley Frith, MDBisi Ademuyiwa, MD, MPH, MSCICynthia Ma, MD, PhDEmily Podany, MDFaisal Fa'ak, MDJingqin (Rosy) Luo, PhDKatherine Clifton, MDMara Hofherr, PharmDNusayba Bagegni, MDRon Bose, MD, PhD

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 2 sitesMO2KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Questions about NCT07914309

Each answer restates registry values shown on this page.

What is NCT07914309?

NCT07914309 is a phase 2 interventional trial sponsored by Washington University School of Medicine. It studies Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine and 5 more drugs in Breast Cancer, Triple Negative Breast Cancer and 1 more condition.

Is NCT07914309 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07914309?

The registry names Faisal Fa'ak, MD (principal investigator, Washington University School of Medicine) as the overall official.

Where does NCT07914309 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07914309 study?

The registered drug and biological interventions are Carboplatin, Cyclophosphamide, Dexamethasone, Diphenhydramine, Doxorubicin, Famotidine, Olanzapine, Paclitaxel and Pembrolizumab.

When is NCT07914309 expected to complete?

The registry lists a primary completion date of 8 Feb 2028 and a study completion date of 31 May 2033. The sponsor last updated the record on 3 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.